Thus, our findings clarify the SKP2/ p27Kip1-independent mechanisms of CKS1B activity in maintaining myeloma cell growth and survival, and also provide a rationale for specifically targeting STAT3 and MEK/ERK/BCL2 in aggressive CKS1B-overexpressing MM. Here, CDKN1B is linked to plasma cell myeloma.